Skip to main content
. Author manuscript; available in PMC: 2014 Dec 2.
Published in final edited form as: Mol Pharm. 2013 Oct 25;10(12):4534–4545. doi: 10.1021/mp400355q

Figure 8.

Figure 8

Comparison of the uptake of the SSCP nanocomplex in different cell lines. (A) Western blot analysis of LDLR in HSC-T6, PC-3 and CaCO-2 cells. (B) Cellular uptake of the SSCP nanocomplex in HSC-T6, PC-3 and CaCO-2 cells. (C) Puromycin, an LDLR inhibitor, reduces the uptake of the SSCP nanocomplex in HSC-T6 cells. Data were shown as mean ±SD (n=3). * p<0.05; ** p<0.01